A study in Frontiers in Pharmacology found that cannabinoids can suppress cancer growth and inflammation, as shown through lab tests, animal studies, and computer modeling.
Researchers examined the ethanol extract of female cannabis, which contained cannabidiol (CBD), tetrahydrocannabinol (THC), and humulene, as identified through GC-MS analysis. In vitro testing on cancer cells showed that the extract significantly slowed their growth, killing 51%–77.6% of them. Further analysis found that CBD, THC, and humulene interacted with key proteins linked to cancer progression, including PD-1/PD-L1, TNF-α, and MMP-9.
In vivo, researchers induced breast cancer in female rats using 7,12-dimethylbenz(a)anthracene (DMBA) and treated them with cannabinoids either individually or in combination. Results showed that the simultaneous use of all three cannabinoids produced the most substantial anticancer and anti-inflammatory effects, leading to significant tumor reduction. The treated groups exhibited decreased serum biomarkers associated with inflammation and tumor progression, highlighting the potential of cannabinoids in breast cancer therapy.
Continue reading